Design, synthesis and evaluation of XZH-5 analogues as STAT3 inhibitors

被引:12
作者
Daka, Philias [1 ]
Liu, Aiguo [2 ]
Karunaratne, Chamini [1 ]
Csatary, Erika [1 ]
Williams, Cameron [1 ]
Xiao, Hui [3 ,4 ]
Lin, Jiayuh [3 ,4 ]
Xu, Zhenghu [5 ]
Page, Richard C. [1 ]
Wang, Hong [1 ]
机构
[1] Miami Univ, Dept Chem & Biochem, Oxford, OH 45056 USA
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Pediat, Wuhan 430030, Hubei Province, Peoples R China
[3] Ohio State Univ, Dept Pediat, Nationwide Childrens Hosp, Ctr Childhood Canc & Blood Dis,Res Inst, Columbus, OH 43210 USA
[4] Ohio State Univ, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA
[5] Shandong Univ, Sch Chem & Chem Engn, Jinan 250100, Peoples R China
关键词
STAT3; Inhibitor; SARs; SH2; Small organic molecule; Molecular docking; POTENT ANTITUMOR-ACTIVITY; SMALL-MOLECULE INHIBITOR; CANCER DRUG DISCOVERY; TRANSCRIPTIONAL CONTROL; ACTIVATION INHIBITOR; SIGNALING PATHWAY; INDUCE APOPTOSIS; MYELOMA CELLS; SH2; DOMAIN; IN-VIVO;
D O I
10.1016/j.bmc.2015.01.025
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Inhibition of the signaling pathways of signal transducer and activator of transcription 3 (STAT 3) has shown to be a promising strategy to combat cancer. In this paper we report the design, synthesis and evaluation of a novel class of small molecule inhibitors, that is, XZH-5 and its analogues, as promising leads for further development of STAT3 inhibitors. Preliminary SARs was established for XZH-5 and its derivatives; and the binding modes were predicted by molecular docking. Lead compounds with IC50 as low as 6.5 mu M in breast cancer cell lines and 7.6 mu M in pancreatic cancer cell lines were identified. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1348 / 1355
页数:8
相关论文
共 50 条
  • [31] Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors
    Zhan, Wenhu
    Xu, Lei
    Dong, Xiaowu
    Dong, Jun
    Yi, Xiao
    Ma, Xiaodong
    Qiu, Ni
    Li, Jia
    Yang, Bo
    Zhou, Yubo
    Hu, Yongzhou
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 117 : 47 - 58
  • [32] Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer
    Walker, Sarah R.
    Xiang, Michael
    Frank, David A.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2014, 382 (01) : 616 - 621
  • [33] STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy
    Hindupur, Sruthi, V
    Schmid, Sebastian C.
    Koch, Jana Annika
    Youssef, Ahmed
    Baur, Eva-Maria
    Wang, Dongbiao
    Horn, Thomas
    Slotta-Huspenina, Julia
    Gschwend, Juergen E.
    Holm, Per Sonne
    Nawroth, Roman
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)
  • [34] Direct Targeting Options for STAT3 and STAT5 in Cancer
    Orlova, Anna
    Wagner, Christina
    de Araujo, Elvin D.
    Bajusz, David
    Neubauer, Heidi A.
    Herling, Marco
    Gunning, Patrick T.
    Keseru, Gyorgy M.
    Moriggl, Richard
    CANCERS, 2019, 11 (12)
  • [35] Design, synthesis and fungicidal evaluation of novel pyraclostrobin analogues
    Wang, Lili
    Zhao, Shuangshuang
    Kong, Xiaotian
    Cao, Lingling
    Tian, Sheng
    Ye, Yonghao
    Qiao, Chunhua
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (04) : 875 - 883
  • [36] Discovery of novel STAT3 DNA binding domain inhibitors
    Wu, Bocheng
    Payero, Benny
    Taylor, Sydney
    Oyelere, Adegboyega K.
    FUTURE MEDICINAL CHEMISTRY, 2021, 13 (15) : 1253 - 1269
  • [37] Identification of a New Series of STAT3 Inhibitors by Virtual Screening
    Matsuno, Kenji
    Masuda, Yoshiaki
    Uehara, Yutaka
    Sato, Hiroshi
    Muroya, Ayumu
    Takahashi, Osamu
    Yokotagawa, Takane
    Furuya, Toshio
    Okawara, Tadashi
    Otsuka, Masami
    Ogo, Naohisa
    Ashizawa, Tadashi
    Oshita, Chie
    Tai, Sachiko
    Ishii, Hidee
    Akiyama, Yasuto
    Asai, Akira
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (08): : 371 - 375
  • [38] Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer
    Li, Haobin
    Wang, Lingling
    Cao, Fei
    Yu, Dehua
    Yang, Jing
    Yu, Xuefei
    Dong, Jinyun
    Qin, Jiang-Jiang
    Guan, Xiaoqing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [39] Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives
    Song, Jiatao
    Wang, Jiawei
    Tian, Sheng
    Li, Huanqiu
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (16) : 1824 - 1847
  • [40] Synthesis and biological evaluation of celastrol derivatives as potent antitumor agents with STAT3 inhibition
    Xu, Shaohua
    Fan, Ruolan
    Wang, Lu
    He, Weishen
    Ge, Haixia
    Chen, Hailan
    Xu, Wen
    Zhang, Jian
    Xu, Wei
    Feng, Yaqian
    Fan, Zhimin
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2022, 37 (01) : 236 - 251